In the Western world, LinkedIn is a staple for many recruitment professionals. It has proven to be a powerful tool for networking, talent sourcing and job postings. But in Japan, people don’t use LinkedIn very much.Here’s why LinkedIn isn’t popular…
HOME > COMMENTARY
COMMENTARY
-
Development Race for Oral Anticoagulants Entering Final Stretch
October 11, 2010
-
How to Eliminate Concerns about Safety of Liovel
October 4, 2010
-
Will It Be Possible to Eliminate Unnecessary Equivalence Studies for Generics?
September 20, 2010
-
Big Pharma Losing Flagships within a Few Years and Shifting Paradigm
September 13, 2010
-
Prior Assessment System Is One Step Forward to Quicker NDA Review
August 2, 2010
-
Industry Needs to Form Consensus on Premium with Med. Institutions
July 26, 2010
-
Japan Should Promote Personalized Cancer Treatment
July 26, 2010
-
METI Reports on “Patent Box”Taxation System in Its Vision 2010
July 5, 2010
-
How Will Generics-Only Companies Will Compete with Major New Entrants?
June 28, 2010
-
Mr Hasegawa Calls For Cooperation with Asian Countries
June 21, 2010
-
PMDA Consultation for Clinical Drug Development in Japan
April 26, 2010
-
Taiyo Needs to Restart from Scratch
April 19, 2010
-
Drug Companies Have No Time to Lose under New Pricing System
March 29, 2010
-
Wholesalers, Pharmacy Chains to Ally to Improve Their Business
March 22, 2010
-
New Pricing System Gives Makers Good Chance to Break from Old Business Practices
March 8, 2010
-
Transfer Limited Financial Resources to Parties Who Make Effort to Provide Better Services
March 1, 2010
-
Korosho Moves to Change Its Vaccine Policy
February 22, 2010
-
Prospects of the Japanese Pharmaceutical Industry in 2010
February 15, 2010
-
Number of Entrants into Market for Biosimilars Increases, But Barriers Are Still High
February 8, 2010
-
New Pricing System to Make e-Detailing More Important
February 1, 2010
ページ
An increasing number of companies in Japan are showing an eagerness to snatch up “drug loss” assets. As of this…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…